Table 1.
Groups | Adjuvant/Carrier1 | Immunogens | Amounts | Site of injection1 | Symbol used in Figure 1 |
PR75–84 wt | IFA | VLVGPTPVNI | 4 × 50 μg | s.c | Downward pointing triangle |
PR75–84 d.mut | IFA | VLVGPTPFNV | 4 × 50 μg | s.c | Black filled Diamond |
PR75–84 d.mut low2 | - | VLVGPTPFNV | 4 × 5 μg | s.c | Blue open Diamond |
RBC-PR75–84 wt | RBC | VLVGPTPVNI biotinylated to synergeneic erythrocytes | 2 × 5 ng3 + 2 × 12.5 ng4 | i.p | Square |
RBC-PR75–84 d.mut | RBC | VLVGPTPFNV biotinylated to syngeneic erythrocytes | 2 × 5 ng3 + 2 × 12.5 ng4 | i.p | Triangle |
RBCempty | RBC | Biotinylated syngeneic erythrocytes | 3 × 200 μl + 1 × 500 μl blood | i.p | Circle |
Untreated | - | - | - | - | Cross |
1 IFA = Incomplete Freunds adjuvant; RBC = Red blood cell; s.c = subcutaneous; i.p = intraperitoneal
2A parallel study
3 Corresponds to 200 μl blood
4 Corresponds to 500 μl blood